FDA cleared expansion Enhatch recently achieved FDA 510(k) clearance for a patient specific instrumentation system for Total Knee Arthroplasty, signaling a validated, market-ready product that can be leveraged to open conversations with orthopedic surgeons and hospital procurement about advanced implants and surgical guides.

XR and AR/VR readiness Strategic partnerships with XR technology providers like Holo-Light demonstrate Enhatch’s capability to deliver immersive visualization and intraoperative streaming, presenting an opportunity to upsell to academic centers and ORs exploring AR/VR training and enhanced planning workflows.

AI powered workflow The AI-driven preoperative planning platform combined with end-to-end scheduling, forecasting, and inventory visibility offers a compelling value proposition for hospitals seeking to reduce operative delays, optimize supply chains, and improve stakeholder communications—a strong cross-sell into OR suites and perioperative teams.

Growth and funding signals Past funding rounds and a multi-million dollar revenue footprint indicate market validation and growing demand for surgical planning software, suggesting prioritization for enterprise deals, channel partnerships, and expansion into multi-site health systems.

Targeted market fit With a focus on orthopedic specialty software and a small but specialized team, Enhatch can pursue account-based selling at mid-to-large hospitals and orthopedic groups that perform total knee arthroplasties, leveraging the unique patient-specific instrumentation offering to differentiate from generalist surgical platforms.